Indeloxazine

Indeloxazine (INN; trade names Elen and Noin) is an antidepressant and cerebral activator^[1][2] that was marketed in Japan and South Korea by Yamanouchi Pharmaceutical Co., Ltd for the treatment of psychiatric symptoms associated with cerebrovascular diseases, namely depression resulting from stroke, emotional disturbance, and avolition.^[3][4] It was marketed from 1988^[4] to 1998, when it was removed from the market reportedly for lack of effectiveness.^[5]

Indeloxazine

Clinical data
Other names	CI-874, YM-08054
ATC code	None
Legal status
Legal status	Discontinued
Identifiers
IUPAC name 2-(3H-Inden-4-yloxymethyl)morpholine
CAS Number	60929-23-9 Y
PubChem CID	3704
ChemSpider	3576 Y
UNII	834M09R1KM
KEGG	D08077 Y
CompTox Dashboard (EPA)	DTXSID30866833
Chemical and physical data
Formula	C14H17NO2
Molar mass	231.295 g·mol−1
3D model (JSmol)	Interactive image
SMILES O(c1cccc2\C=C/Cc12)CC3OCCNC3
InChI InChI=1S/C14H17NO2/c1-3-11-4-2-6-14(13(11)5-1)17-10-12-9-15-7-8-16-12/h1-4,6,12,15H,5,7-10H2 Y Key:MADRVGBADLFHMO-UHFFFAOYSA-N Y
(verify)

Indeloxazine acts as a serotonin releasing agent, norepinephrine reuptake inhibitor, and NMDA receptor antagonist.^[6][7] It has been found to enhance acetylcholine release in the rat forebrain through activation of the 5-HT₄ receptor via its action as a serotonin releasing agent.^[8][9][10] The drug has been found to possess nootropic,^[11][12] neuroprotective,^{[13][14][15][16]} anticonvulsant,^[17] and antidepressant-like effects in animal models.^[1][6]